Should I buy or sell Ekso Bionics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks .

What is Ekso Bionics' stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for Ekso Bionics' stock. Their EKSO share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts .

How have EKSO shares performed in 2023?

Ekso Bionics' stock was trading at $1.19 at the beginning of the year. Since then, EKSO stock has increased by 31.1% and is now trading at $1.56. View the best growth stocks for 2023 here .

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 71,100 shares, an increase of 109.7% from the October 31st total of 33,900 shares. Based on an average daily trading volume, of 69,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.6% of the company's shares are short sold. View Ekso Bionics' Short Interest .

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our EKSO earnings forecast .

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings data on Thursday, October, 26th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. The firm earned $4.61 million during the quarter, compared to the consensus estimate of $4.53 million. Ekso Bionics had a negative net margin of 89.28% and a negative trailing twelve-month return on equity of 76.01%.

When did Ekso Bionics' stock split?

Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI) , Gran Tierra Energy (GTE) , KushCo (KSHB) , CNBX Pharmaceuticals (CNBX) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Bionano Genomics (BNGO) , Novan (NOVN) , Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA) .

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.55%), Strategic Wealth Investment Group LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman. View institutional ownership trends .

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Ekso Bionics Stock Price, News & Analysis (NASDAQ:EKSO)

$1.56

-0.10 (-6.02%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.56
▼
$1.68
50-Day Range: $0.68
▼
$1.75
52-Week Range: $0.62
▼
$1.88

Volume: 54,856 shs
Average Volume: 45,774 shs
Market Capitalization: $22.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Ekso Bionics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 476.9% Upside
$9.00 Price Target
Short Interest: Healthy
0.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.29) to ($0.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

570th out of 957 stocks

General Industrial Machinery, Industry

6th out of 8 stocks

3.5

Analyst's Opinion

Consensus Rating
Ekso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Ekso Bionics has a forecasted upside of 476.9% from its current price of $1.56.
Amount of Analyst Coverage
Ekso Bionics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.61% of the float of Ekso Bionics has been sold short.
Short Interest Ratio / Days to Cover
Ekso Bionics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ekso Bionics has recently increased by 109.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ekso Bionics does not currently pay a dividend.
Dividend Growth
Ekso Bionics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EKSO.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Ekso Bionics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for EKSO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ekso Bionics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Ekso Bionics is held by insiders.
Percentage Held by Institutions
Only 9.54% of the stock of Ekso Bionics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ekso Bionics are expected to grow in the coming year, from ($1.29) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ekso Bionics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ekso Bionics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ekso Bionics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ekso Bionics Stock (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

EKSO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EKSO Stock News Headlines

December 3, 2023 | americanbankingnews.com

Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

November 16, 2023 | finance.yahoo.com

Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 2, 2023 | finance.yahoo.com

Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal

October 27, 2023 | finanznachrichten.de

Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%

October 27, 2023 | finance.yahoo.com

Q3 2023 Ekso Bionics Holdings Inc Earnings Call

October 27, 2023 | finance.yahoo.com

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call Transcript

October 26, 2023 | seekingalpha.com

Ekso Bionics Holdings, Inc. (EKSO) Q3 2023 Earnings Call Transcript

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 26, 2023 | msn.com

Ekso Bionics Holdings GAAP EPS of -$0.24, revenue of $4.6M

October 26, 2023 | finance.yahoo.com

Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%

October 25, 2023 | msn.com

Ekso Bionics Holdings Q3 Earnings Preview

October 19, 2023 | finance.yahoo.com

Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023

September 27, 2023 | finance.yahoo.com

Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category

September 22, 2023 | seekingalpha.com

EKSO Ekso Bionics Holdings, Inc.

September 11, 2023 | finance.yahoo.com

Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

September 9, 2023 | benzinga.com

Ekso Bionics Holdings Stock (NASDAQ:EKSO) Dividends: History, Yield and Dates

August 25, 2023 | benzinga.com

Bionic Devices market is projected to grow at a CAGR of 9.5% by 2033: Visiongain

July 28, 2023 | seekingalpha.com

Ekso Bionics Holdings, Inc. (EKSO) Q2 2023 Earnings Call Transcript

July 28, 2023 | finanznachrichten.de

Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023

July 28, 2023 | msn.com

Ekso Bionics Holdings GAAP EPS of -$0.31 misses by $0.03, revenue of $4.7M beats by $0.35M

July 28, 2023 | finance.yahoo.com

Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023

July 28, 2023 | finance.yahoo.com

Q2 2023 Ekso Bionics Holdings Inc Earnings Call

July 20, 2023 | finance.yahoo.com

Ekso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023

July 14, 2023 | au.finance.yahoo.com

EKSO - Ekso Bionics Holdings, Inc.

May 15, 2023 | marketwatch.com

Healthcare Assistive Robot Market Expected Growth, Demand and Trends for 2030 | Barrett Technology, Cyberdyne, Ekso Bionics

May 11, 2023 | marketwatch.com

Human Augmentation Market Report Covers Future Trends with Research 2023-2029 | B-Temia, BrainGate, Ekso Bionics

See More Headlines

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/26/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: General industrial machinery,
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EKSO
Previous Symbol: OTCMKTS:EKSOD
CUSIP: N/A
CIK: 1549084
Web: www.eksobionics.com
Phone: (510) 984-1761
Fax: 510-927-2647
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $9.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +476.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,080,000.00
Net Margins: -89.28%
Pretax Margin: -89.28%
Return on Equity: -76.01%
Return on Assets: -42.36%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 2.85
Quick Ratio: 2.15

Sales & Book Value

Annual Sales: $12.91 million
Price / Sales: 1.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.94 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 14,230,000
Free Float: 13,167,000
Market Cap: $22.20 million
Optionable: Not Optionable
Beta: 1.87

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Scott G. Davis (Age 53)
CEO & Director
Comp: $535.8k
Mr. Jerome Wong (Age 49)
Corporate Controller, Corporate Secretary & CFO
Comp: $356.81k
Mr. Jason C. Jones
Chief Operating Officer
Ms. Rachael Anderson
Global Director of Marketing & Strategic Growth
Mr. Anthony Pratt
Vice President of Sales
Ms. Ann Cookson
Human Resources Director
Ms. Foon Lim Chwee
President of APAC
Mr. Stephan Aderhold
Senior VP & GM of EMEA

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EKSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.
What is Ekso Bionics' stock price target for 2024?: 1 equities research analysts have issued twelve-month price targets for Ekso Bionics' stock. Their EKSO share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.
How have EKSO shares performed in 2023?: Ekso Bionics' stock was trading at $1.19 at the beginning of the year. Since then, EKSO stock has increased by 31.1% and is now trading at $1.56.
View the best growth stocks for 2023 here.
Are investors shorting Ekso Bionics?: Ekso Bionics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 71,100 shares, an increase of 109.7% from the October 31st total of 33,900 shares. Based on an average daily trading volume, of 69,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.6% of the company's shares are short sold.
View Ekso Bionics' Short Interest.
When is Ekso Bionics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our EKSO earnings forecast.
How were Ekso Bionics' earnings last quarter?: Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings data on Thursday, October, 26th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. The firm earned $4.61 million during the quarter, compared to the consensus estimate of $4.53 million. Ekso Bionics had a negative net margin of 89.28% and a negative trailing twelve-month return on equity of 76.01%.

When did Ekso Bionics' stock split?: Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Ekso Bionics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).
Who are Ekso Bionics' major shareholders?: Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.55%), Strategic Wealth Investment Group LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends.
How do I buy shares of Ekso Bionics?: Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EKSO) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial